Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Exploring once-daily tenofovir + 3TC + abacavir: an argument for clinical-trials-based data.


In the first formally presented data on once-daily tenofovir + 3TC + abacavir, the regimen is shown to be suboptimal. Problem is, clinicians have already been using it.